CClinicalTrials.gg
Not yet recruitingNCT06661343C4+3MVUpdated May 18, 2026

Pre-exposure Prophylaxis (PrEP) Adherence for Black MSM

An interventional study of C4 Program and C4 + 3MV Program in HIV Prevention, sponsored by Yale University. Not yet recruiting at 2 sites in United States. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by Yale University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

The goal of this clinical trial is to learn if two interventions-C4 and C4+3MV-can improve PrEP adherence (taking medication to prevent HIV) among Black men who have sex with men (MSM). The study will also explore the most effective ways to support participants in continuing their PrEP use over time.

The main questions it aims to answer are:

  • Does the C4 program help participants take PrEP more regularly?
  • Does adding the 3MV intervention to C4 provide additional support for adherence?

Researchers will compare two intervention strategies to see if they result in better PrEP adherence:

  • C4 Intervention: A program focused on individualized care coordination and addressing structural needs.
  • C4 + 3MV Intervention: A combination of care coordination with additional behavioral change sessions.

Participants will:

  • Participate in PrEP education and counseling sessions.
  • Have their PrEP use monitored through dried blood spot (DBS) tests.
  • Complete questionnaires about their experiences and challenges with PrEP. Receive support sessions tailored to address individual barriers to PrEP adherence.
Read the detailed description

This clinical trial aims to evaluate two intervention strategies-C4 and C4 + 3MV-to improve adherence to PrEP (pre-exposure prophylaxis) among Black men who have sex with men (MSM) in two metropolitan areas: Dallas/Fort Worth and New York City. The study addresses structural and behavioral barriers to PrEP adherence, aiming to reduce disparities in HIV prevention efforts.

Study Design and Methodology:

  • Trial Type: Multi-site, staircase stepped-wedge randomized controlled trial (RCT)
  • Duration: 24 months total, with 9-month intervention periods for each group
  • Participants: 500 participants (Texas n=150 and NYC n=350); Participants are recruited from community-based organizations and through network-based referrals

Randomization:

  • 48 networks will be randomized into 8 sequences.
  • Each network will experience a 3-month control period, followed by either the C4 intervention or the C4 + 3MV intervention.

Interventions:

  • C4 Intervention: Focuses on care coordination, addressing participants' needs related to healthcare access, stigma, and mental health services. Uses individualized care plans and support systems to facilitate adherence.
  • C4 + 3MV Intervention: Incorporates both care coordination and the 3MV (Many Men, Many Voices) behavioral change program. 3MV focuses on reducing stigma, promoting safe behaviors, and improving self-efficacy through group sessions.

Primary and Secondary Outcomes:

  • Primary Outcome: PrEP adherence, measured through dried blood spot (DBS) assays to assess drug levels over time.
  • Secondary Outcomes: Changes in HIV-related health-seeking behavior (e.g., frequency of HIV testing); Autonomy and social support, measured through validated scales; Reduction in stigma and mental health improvements

Data Collection and Monitoring:

  • Data will be collected at multiple points using questionnaires, DBS tests, and counseling session evaluations.
  • A Learn-as-You-Go (LAGO) adaptive analysis will be conducted every 6 months to optimize intervention delivery.
02

Conditions studied

  • HIV Prevention

Keywords

  • HIV
  • PrEP
  • Black MSM
  • Stigma Reduction
  • Client Centered Care Coordination
  • Many Men Many Voices
  • Evidence-based Intervention
03

In context

Lead sponsor

Yale University is the lead sponsor of 1,724 studies on the registry; 298 are open to participants now.

Of its 210 completed or terminated interventional studies of FDA-regulated products, 126 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • Self-identify as male.
  • Self-Identify as Black people.
  • Aged 18 or older.
  • Self Report having sex with men in the past 6 months.
  • Eligible for PrEP or currently prescribed PrEP.
  • Willing to participate in behavioral intervention sessions.

Exclusion criteria

Exclusion Criteria:

  • Currently diagnosed with HIV.
  • Unable to provide informed consent.
  • Unable to fully engage with the intervention due to health issues.
  • Participating in another clinical trial with conflicting outcomes.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    C4 Intervention

    Participants in this arm will receive care coordination and support through the C4 intervention. This program focuses on addressing structural barriers, such as healthcare access and mental health, to improve PrEP adherence. Participants will also attend regular counseling sessions and have their PrEP use monitored through dried blood spot (DBS) tests.

    Behavioral: C4 Program

  • Experimental
    C4 + 3MV Intervention

    Participants in this arm will receive the C4 intervention, along with the 3MV (Many Men, Many Voices) behavioral intervention. The 3MV program aims to reduce stigma, promote safer behaviors, and increase self-efficacy. This arm integrates both structural and behavioral approaches to enhance PrEP adherence. Participants will complete counseling sessions, group activities, and DBS testing for monitoring adherence.

    Behavioral: C4 + 3MV Program

Interventions

  • BehavioralC4 Program

    The C4 intervention is a behavioral program designed to provide care coordination to address structural barriers to PrEP adherence among Black men who have sex with men (MSM). It includes personalized support services, focusing on healthcare access, mental health, and stigma reduction to promote consistent PrEP use. Participants will receive counseling sessions and follow-ups based on their individual needs.

    Also known as: Client Centered Care Coordination

  • BehavioralC4 + 3MV Program

    This intervention combines the C4 care coordination with the 3MV behavioral program. The 3MV program focuses on behavior change, addressing self-efficacy, stigma, and promoting healthy practices. Through this combination, participants receive both structural and behavioral support to maximize their adherence to PrEP.

    Also known as: Many Men Many Voices and Client Centered Care Coordination Integrated Intervention

06

What researchers measure

Primary outcomes

  1. PrEP adherence- self report

    PrEP adherence will be assessed through self-report. Self-reported adherence is measured by doses taken in the past 30 days, with fewer missed doses indicating higher adherence.

    Time frame: 0, 3, 6, 9, 12 months

  2. PrEP adherence- biomarker validation

    PrEP adherence will be assessed through biomarker validation using dried blood samples. A tenofovir disoproxil fumarate (TFV-DF) level \>700 fmol/punch confirms adherence.

    Time frame: 0, 6, and 12 months

Secondary outcomes

  1. HIV Testing Frequency

    HIV testing frequency will be assessed by the number of tests taken in the past 90 days, with more tests indicating higher engagement in testing

    Time frame: Every 3 months for 12 months

Other outcomes

  1. Perceived Competence for PrEP use

    Perceived Competence for PrEP Use Scale will measure participants' confidence in their ability to follow PrEP recommendations. Scores range from 9 to 45, with higher scores reflecting greater competence.

    Time frame: Baseline, 6 months, and 12 months

  2. PrEP Use Self-Regulation

    PrEP Use Self-Regulation Questionnaire will assess participants' internalization of autonomous motivation to maintain adherence to PrEP. Scores range from 9 to 45, with higher scores indicating stronger self-regulation.

    Time frame: Baseline, 6 months, and 12 months

  3. Basic Needs Satisfaction Scale

    The Basic Needs Satisfaction Scale (9 items) assesses participants' fulfillment of psychological needs (autonomy, competence, and relatedness) within social relationships, especially from close friends. Scores range from 9 to 45, with higher scores indicating greater satisfaction.

    Time frame: Every 3 months for 12 months

  4. Healthcare Climate Questionnaire

    The Healthcare Climate Questionnaire (15 items) will measure participants' perception of their healthcare providers' support. Scores range from 15 to 75, with higher scores reflecting a more supportive healthcare environment.

    Time frame: Baseline, 6, and 12 months

  5. Depression (PHQ-9)

    Depression will be assessed using the PHQ-9. PHQ-9 is a 9-item validated questionnaire used to screen for depression with a range of scores from 0-27. A cumulative score of ≥10 is considered positive with lower scores indicating no or mild anxiety.

    Time frame: Baseline, 6 months, and 12 months

  6. HIV Stigma Scale

    Intersectional stigma will be measured across four subscales: Enacted Stigma (10 items) Vicarious Stigma (10 items) Perceived Stigma (10 items) Internalized Stigma (10 items) Each subscale ranges from 10 to 50, with higher scores indicating more stigma experienced.

    Time frame: Baseline, 3, 6, 9, and 12 months

  7. Quality Client Perception of Coordination Quality

    The Client Perception of Coordination Quality Questionnaire will assess participants' satisfaction with healthcare services. Scores range from 3 to 15, with higher scores indicating better care coordination.

    Time frame: Baseline, 6 months, and 12 months

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Yes — Investigators plan to share de-identified participant data, including information on PrEP usage, behavioral intervention participation, survey responses, and biological specimen results (e.g., dried blood spot test results). The shared data will support future research on HIV prevention and PrEP adherence, ensuring participant privacy throughout the process.

Supporting information: Study protocol, Sap, Icf

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06661343
Lead sponsor
Yale University
Collaborators
National Institute of Mental Health (NIMH)
Responsible party
Sponsor
First posted
Oct 28, 2024
Start date
Aug 1, 2026 (estimated)
Primary completion
Jan 1, 2029 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
May 18, 2026

Study contacts

Raquel Ramos, PhD, MBA, MSN, FNYAM, FAHA
Contact
ysn.c4_3mvstudy@yale.edu
203-737-2339
LaRon Nelson, PhD, RN, FNP, FNAP, FNYAM, FAA
Contact
ysn.c4_3mvstudy@yale.edu
203-785-5797

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion